Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
CONCLUSIONS: Advanced NSCL patients treated with carboplatin or cisplatin doublet with third-generation chemotherapy drugs showed equivalent overall survival, one-year survival, and response rate. Regarding adverse events, carboplatin caused more thrombocytopenia, and cisplatin caused more nausea/vomiting. Therefore, in this palliative therapeutic intent, the choice of the platin compound should take into account the expected toxicity profile, patient's comorbidities and preferences.
PMID: 31930743 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB, Riera R Tags: Cochrane Database Syst Rev Source Type: research
More News: Alopecia | Anemia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | General Medicine | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Palliative | Statistics | Study | Thrombocytopenia | Toxicology